Mylan snags Merck's generic business

Mylan Laboratories will become the third-largest generic drug company in the world (behind Teva and Novartis) after signing a definitive agreement under which it will acquire Merck's generic business in a deal worth $6.7 billion. Industry observers noted that the acquisition will place Mylan in the number three slot behind Teva and Novartis with a significant presence in all of the top five global generic markets.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, .